ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2025
Patient-reported quality of life in adolescents and young adults with melanoma.
Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Pediatric Melanoma: Emerging Therapies and Ongoing Clinical Trials.Dermatology and therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
purposeAdolescents and young adults (AYAs, diagnosed between 15-39 years) with melanoma experience unique challenges distinct from those experienced by children and older adults. This study aims to evaluate health-related quality of life (HRQOL) in AYAs with melanoma and identify factors correlated with HRQOL outcomes.
methodsA cohort of 45 AYAs with melanoma was surveyed to assess HRQOL across multiple domains, including physical, emotional, and social functioning. Data were analyzed to compare HRQOL in patients undergoing active treatment versus those in post-treatment survivorship and between those treated with ICBs and those never treated with ICBs.
resultsAYAs reported impaired HRQOL across all domains. Over 60% reported mild to severe levels of anxiety, with 68% of females affected. More patients on active treatment, compared with those in post-treatment survivorship, reported impairment in physical function (64% vs 20%, p < 0.001), depression (52% vs 16%, p = 0.028), fatigue (60% vs 21%, p = 0.005), sleep disturbance (48% vs 21%, p = 0.013), pain interference (68% vs 16%, p < 0.001), and impaired social roles (32% vs 5%, p = 0.004). Patients receiving ICBs, compared with those never treated with ICBs, reported worse anxiety (76% vs 37%, p = 0.042) and fatigue (56% vs 26%, p = 0.036) and greater sleep disturbance (52% vs 16%, p = 0.002), and impaired social roles (28% vs 11%, p = 0.004).
conclusionAYAs with melanoma experience elevated levels of distress and impaired HRQOL, particularly during active treatment and with ICB use. Interventions targeting HRQOL are essential to address the unique needs of this vulnerable population.
Indexed as
Identifiers
41219535What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.